Delivery Order HHSD200200100081I-HHSD2002001000810027

The National Institute of Allergy and Infectious Diseases awarded a $21.9 million definitive contract to MRIGlobal (doing business as Midwest Research Institute) on November 17, 2023, for the Mycobacterium Tuberculosis Quality Assessment Program. This cost-plus-fixed-fee contract, which extends through November 2030, supports NIAID clinical trials by establishing quality control and proficiency testing capabilities for tuberculosis diagnostic laboratories. MRIGlobal will operate a...

This is a SBIR Phase I contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), which is part of the Department of Health and Human Services (HHS), to Nanocomposix, Inc., a small business manufacturer of engineered nanoparticles. The contract has a firm fixed price of $300,000.00 and is for the development of a point-of-care test to measure antibiotic concentrations in the blood for tuberculosis (TB) treatment. Nanocomposix has prior experience providing products...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $9.85M cost-no-fee definitive contract to The Global Alliance For TB Drug Development Inc. (TB Alliance) on May 10, 2024, to develop a novel modulator targeting proteostasis for the treatment of Mycobacterium tuberculosis. The contract, which extends through April 30, 2028, will be performed in New York, NY and was competitively solicited with a posting date of January 11, 2023, and an April 11, 2023 due date. No...

Research Triangle Institute (RTI) International was awarded a $707,813 time and materials contract by the Department of Health and Human Services Centers for Disease Control and Prevention to provide cost effectiveness analysis services for the Tuberculosis Epidemiologic Studies Consortium III (TBESC-III). The contract calls for RTI to design and implement cost effectiveness analyses of clinical interventions to improve performance across the latent tuberculosis infection care cascade. RTI...

This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Akonni Biosystems Inc. The $299,976 firm fixed price contract is for the development of a "LOW COST INTEGRATED METHOD FOR ISOLATION OF M. TUBERCULOSIS DNA FROM RAW SPUTUM". The contract has a total small business set-aside designation. Akonni Biosystems is a molecular diagnostics...

This is a firm fixed-price purchase order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to the International Tuberculosis Research Center (ITRC) on August 14, 2014 for the "LTBI STUDY (2ND YEAR)" project. The contract has a ceiling value of $150,000.00 and a completion date of August 14, 2014. The contract is not designated as a set-aside. Based on the project title, this contract appears to be part of NIAID's larger efforts related to the...

This is a purchase order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to the National Institute For Research In Tuberculosis, a non-profit organization that operates as a hospital. The $537,500.00 firm fixed price award is to provide support to conduct studies on tuberculosis in India. The contract has a performance period ending on May 31, 2019 and was awarded on November 30, 2015. No set-aside was used for this contract. The National...

The U.S. National Institute of Allergy and Infectious Diseases (NIAID) awarded a $110,000.00 firm fixed price purchase order to the National Institute for Research in Tuberculosis in India. The order is for unspecified "other functions" related to tuberculosis research. The award does not have a set-aside designation and was completed on January 27, 2014. The National Institute for Research in Tuberculosis is an international non-profit organization that has previously participated...

The Centers for Disease Control and Prevention (CDC) awarded a $4,455,976 cost-no-fee definitive contract to The Regents of the University of California, San Francisco (UCSF) to develop, implement, and evaluate interventions to improve latent tuberculosis infection (LTBI) identification and treatment among high-risk non-U.S.-born populations in primary care settings. This contract, known as Tuberculosis Epidemiologic Studies Consortium III (TBESC3), has a period of performance from September 29,...

This is a $1,486,937 definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services, to PAI Life Sciences Inc., a self-certified small disadvantaged business. The contract is for the development of an inhaled drug combination for tuberculosis therapy under the SBIR Phase II program. Key tasks include the manufacture of spray-dried combination drugs, technical support for pharmacokinetic and...